| 摘要 |
Disclosed herein is the use of a synergistically effective amount of lenalidomide, at least one corticosteroid, and at least one immunoconjugate, in the manufacture of a medicament for treating or modulating the growth of a cancer cell population, wherein the immunoconjugate comprises at least one cell-binding agent that binds to CD56 and at least one anti-mitotic agent, wherein the cell-binding agent is an antibody, a single chain antibody or an antigen-binding antibody fragment.
|
